Heart DiseasesHeH BioBankNCT06976502
Health eHeart BioBank
An observational study of Heart Diseases and Cardiac Diseases, run by University of California, San Francisco at 1 site in United States.
Trial summary
The purpose of the Health eHeart BioBank is to collect and store specimen (e.g. blood, DNA, tissue) for future studies at the University of California, San Francisco (UCSF) that will help determine changes and identify molecular and genetic markers in the human body that might help increase our knowledge of heart… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Heart Diseases, Cardiac Diseases, Vascular Diseases
- What is being tested?
- Blood Draw, Tissue Collection and DNA Collection
- Type of treatment
- Surgery or procedure
- How many people
- 500,000 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2025to Dec 2035
- How long will I take part?
- 20 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Study population are patients of the University of California, San Francisco and their relatives.
Who may be able to join
- Age ≥ 18 years or older.
- And at least one of the following:
- Established patient seen at UCSF and/or is a current participant in a clinical study that utilizes the HeH BioBank for biospecimen collection.
- Family member of a patient with cardiovascular disease.
- Patient with no cardiovascular disease.
Who cannot join
- Unwilling to consent to biospecimen collection through the HeH BioBank.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of California, San Francisco
San Francisco, California, 94158
About this study
The purpose of the Health eHeart BioBank is to collect and store specimen (e.g. blood, DNA, tissue) for future studies at the University of California, San Francisco (UCSF) that will help determine changes and identify molecular and genetic markers in the human body that might help increase our knowledge of heart disease and guide development of new diagnostic tools and treatments that may help rapidly detect heart disease and prevent and/or treat heart disease.
- Being tested
- Blood Draw, Tissue Collection, DNA Collection, Medical Chart Review
- Keywords
- Heart Disease, Cardiovascular Disease, Cardiology
- Medical subject headings
- Heart Diseases, Vascular Diseases, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood DrawProcedure or surgery
Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.
Tissue CollectionProcedure or surgery
If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.
DNA CollectionProcedure or surgery
Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.
Medical Chart ReviewOther
Also called Medical Record Review
Demographic, clinical, and pathologic information will be extracted from the participant's medical record.
| Study group | Role | What they receive |
|---|---|---|
| Participants with a History of Cardiovascular Disease | Not described Receives: Procedure: Blood Draw; Procedure: Tissue Collection; Procedure: DNA Collection; Other: Medical Chart Review | |
| Participants with a Family History of Cardiovascular Disease | Not described Receives: Procedure: Blood Draw; Procedure: Tissue Collection; Procedure: DNA Collection; Other: Medical Chart Review | |
| Healthy Controls | Not described Receives: Procedure: Blood Draw; Procedure: Tissue Collection; Procedure: DNA Collection; Other: Medical Chart Review |
What is being measured
The primary outcome is the main question the study is designed to answer.
Establish and Maintain a Centralized Biorepository
Establish and maintain a centralized biorepository to collect and store a variety of biospecimen samples and clinical data.
This would allow for the samples and clinical data to be used to test hypotheses regarding the molecular and genetic basis of diagnosis and treatment of cardiovascular diseases.
Measured: Up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2025
- Study start1 Apr 2025
- Primary completionDec 2035 (estimated)
- Study completionDec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Heart DiseasesStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 500,000 participants (estimated)
- Target duration
- 20 Years
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jeffrey E Olgin, MD, Principal investigator, University of California, San FranciscoGregory Marcus, MD, Principal investigator, University of California, San FranciscoVasanth Vedantham, MD, Principal investigator, University of California, San FranciscoConnor G O'Brien, MD, Principal investigator, University of California, San FranciscoJames P Pirruccello, MD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06976502
- Sponsor's protocol ID
- 24-40979
- Acronym
- HeH BioBank
- Status last verified
- Jul 2026
- First submitted
- 8 May 2025
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Rahmutula D, Marcus GM, Wilson EE, Ding CH, Xiao Y, Paquet AC, Barbeau R, Barczak AJ, Erle DJ, Olgin JE. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-beta1. Cardiovasc Res. 2013 Sep 1;99(4):769-79. doi: 10.1093/cvr/cvt074. Epub 2013 Apr 23.
PubMed 23612580Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, Yeh C, Colburn B, Clark NM, Khan R, Hart AP, Moffatt E. Prospective Countywide Surveillance and Autopsy Characterization of Sudden Cardiac Death: POST SCD Study. Circulation. 2018 Jun 19;137(25):2689-2700. doi: 10.1161/CIRCULATIONAHA.117.033427.
PubMed 29915095Aouizerat BE, Vittinghoff E, Musone SL, Pawlikowska L, Kwok PY, Olgin JE, Tseng ZH. GWAS for discovery and replication of genetic loci associated with sudden cardiac arrest in patients with coronary artery disease. BMC Cardiovasc Disord. 2011 Jun 10;11:29. doi: 10.1186/1471-2261-11-29.
PubMed 21658281Roberts JD, Hsu JC, Aouizerat BE, Pullinger CR, Malloy MJ, Kane JP, Olgin JE, Marcus GM. Impact of a 4q25 genetic variant in atrial flutter and on the risk of atrial fibrillation after cavotricuspid isthmus ablation. J Cardiovasc Electrophysiol. 2014 Mar;25(3):271-277. doi: 10.1111/jce.12317. Epub 2013 Dec 13.
PubMed 24237655Roberts JD, Dewland TA, Glidden DV, Hoffmann TJ, Arking DE, Chen LY, Psaty BM, Olgin JE, Alonso A, Heckbert SR, Marcus GM. Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. Am Heart J. 2016 May;175:9-17. doi: 10.1016/j.ahj.2016.02.002. Epub 2016 Feb 13.
PubMed 27179719Roberts JD, Dewland TA, Longoria J, Fitzpatrick AL, Ziv E, Hu D, Lin J, Glidden DV, Psaty BM, Burchard EG, Blackburn EH, Olgin JE, Heckbert SR, Marcus GM. Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1026-32. doi: 10.1161/CIRCEP.114.001781. Epub 2014 Nov 8.
PubMed 25381796Marcus GM, Smith LM, Glidden DV, Wilson E, McCabe JM, Whiteman D, Tseng ZH, Badhwar N, Lee BK, Lee RJ, Scheinman MM, Olgin JE. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm. 2008 Feb;5(2):215-21. doi: 10.1016/j.hrthm.2007.10.007. Epub 2007 Oct 7.
PubMed 18242542Roberts JD, Longoria J, Poon A, Gollob MH, Dewland TA, Kwok PY, Olgin JE, Deo RC, Marcus GM. Targeted deep sequencing reveals no definitive evidence for somatic mosaicism in atrial fibrillation. Circ Cardiovasc Genet. 2015 Feb;8(1):50-7. doi: 10.1161/CIRCGENETICS.114.000650. Epub 2014 Nov 18.
PubMed 25406240Marcus GM, Rosenthal DG, Nah G, Vittinghoff E, Fang C, Ogomori K, Joyce S, Yilmaz D, Yang V, Kessedjian T, Wilson E, Yang M, Chang K, Wall G, Olgin JE. Acute Effects of Coffee Consumption on Health among Ambulatory Adults. N Engl J Med. 2023 Mar 23;388(12):1092-1100. doi: 10.1056/NEJMoa2204737.
PubMed 36947466
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Health eHeart BioBank
- ClinicalTrials.gov ID
- NCT06976502
- Acronym / sponsor ID
- HeH BioBank / 24-40979
- Keywords
- Heart Disease, Cardiovascular Disease, Cardiology
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 500,000 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- Dec 2035 (estimated)
- Study completion
- Dec 2035 (estimated)
- First posted
- 16 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the Health eHeart BioBank is to collect and store specimen (e.g. blood, DNA, tissue) for future studies at the University of California, San Francisco (UCSF) that will help determine changes and identify molecular and genetic markers in the human body that might help increase our knowledge of heart disease and guide development of new diagnostic tools and treatments that may help rapidly detect heart disease and prevent and/or treat heart disease.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 20 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Participants with a History of Cardiovascular Disease | – | Procedure: Blood Draw, Procedure: Tissue Collection, Procedure: DNA Collection, Other: Medical Chart Review |
| Participants with a Family History of Cardiovascular Disease | – | Procedure: Blood Draw, Procedure: Tissue Collection, Procedure: DNA Collection, Other: Medical Chart Review |
| Healthy Controls | – | Procedure: Blood Draw, Procedure: Tissue Collection, Procedure: DNA Collection, Other: Medical Chart Review |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Study population are patients of the University of California, San Francisco and their relatives.
Key inclusion criteria (5 listed)
- Age ≥ 18 years or older.
- Established patient seen at UCSF and/or is a current participant in a clinical study that utilizes the HeH BioBank for biospecimen collection.
- Family member of a patient with cardiovascular disease.
- Patient with no cardiovascular disease.
Key exclusion criteria (1 listed)
- Unwilling to consent to biospecimen collection through the HeH BioBank.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood DrawParticipants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study. | Procedure or surgery | Healthy Controls, Participants with a Family History of Cardiovascular Disease, Participants with a History of Cardiovascular Disease |
| Tissue CollectionIf the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure. | Procedure or surgery | Healthy Controls, Participants with a Family History of Cardiovascular Disease, Participants with a History of Cardiovascular Disease |
| DNA CollectionParticipants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw. | Procedure or surgery | Healthy Controls, Participants with a Family History of Cardiovascular Disease, Participants with a History of Cardiovascular Disease |
| Medical Chart ReviewAlso: Medical Record ReviewDemographic, clinical, and pathologic information will be extracted from the participant's medical record. | Other | Healthy Controls, Participants with a Family History of Cardiovascular Disease, Participants with a History of Cardiovascular Disease |
Primary outcome
Establish and Maintain a Centralized Biorepository
Time frame: Up to 10 years
Establish and maintain a centralized biorepository to collect and store a variety of biospecimen samples and clinical data. This would allow for the samples and clinical data to be used to test hypotheses regarding the molecular and genetic basis of diagnosis and treatment of cardiovascular diseases.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Background: PubMed 23612580Rahmutula D, Marcus GM, Wilson EE, Ding CH, Xiao Y, Paquet AC, Barbeau R, Barczak AJ, Erle DJ, Olgin JE. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-beta1. Cardiovasc Res. 2013 Sep 1;99(4):769-79. doi: 10.1093/cvr/cvt074. Epub 2013 Apr 23.
- Background: PubMed 29915095Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, Yeh C, Colburn B, Clark NM, Khan R, Hart AP, Moffatt E. Prospective Countywide Surveillance and Autopsy Characterization of Sudden Cardiac Death: POST SCD Study. Circulation. 2018 Jun 19;137(25):2689-2700. doi: 10.1161/CIRCULATIONAHA.117.033427.
- Background: PubMed 21658281Aouizerat BE, Vittinghoff E, Musone SL, Pawlikowska L, Kwok PY, Olgin JE, Tseng ZH. GWAS for discovery and replication of genetic loci associated with sudden cardiac arrest in patients with coronary artery disease. BMC Cardiovasc Disord. 2011 Jun 10;11:29. doi: 10.1186/1471-2261-11-29.
- Background: PubMed 24237655Roberts JD, Hsu JC, Aouizerat BE, Pullinger CR, Malloy MJ, Kane JP, Olgin JE, Marcus GM. Impact of a 4q25 genetic variant in atrial flutter and on the risk of atrial fibrillation after cavotricuspid isthmus ablation. J Cardiovasc Electrophysiol. 2014 Mar;25(3):271-277. doi: 10.1111/jce.12317. Epub 2013 Dec 13.
- Background: PubMed 27179719Roberts JD, Dewland TA, Glidden DV, Hoffmann TJ, Arking DE, Chen LY, Psaty BM, Olgin JE, Alonso A, Heckbert SR, Marcus GM. Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. Am Heart J. 2016 May;175:9-17. doi: 10.1016/j.ahj.2016.02.002. Epub 2016 Feb 13.
- Background: PubMed 25381796Roberts JD, Dewland TA, Longoria J, Fitzpatrick AL, Ziv E, Hu D, Lin J, Glidden DV, Psaty BM, Burchard EG, Blackburn EH, Olgin JE, Heckbert SR, Marcus GM. Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1026-32. doi: 10.1161/CIRCEP.114.001781. Epub 2014 Nov 8.
- Background: PubMed 18242542Marcus GM, Smith LM, Glidden DV, Wilson E, McCabe JM, Whiteman D, Tseng ZH, Badhwar N, Lee BK, Lee RJ, Scheinman MM, Olgin JE. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm. 2008 Feb;5(2):215-21. doi: 10.1016/j.hrthm.2007.10.007. Epub 2007 Oct 7.
- Background: PubMed 25406240Roberts JD, Longoria J, Poon A, Gollob MH, Dewland TA, Kwok PY, Olgin JE, Deo RC, Marcus GM. Targeted deep sequencing reveals no definitive evidence for somatic mosaicism in atrial fibrillation. Circ Cardiovasc Genet. 2015 Feb;8(1):50-7. doi: 10.1161/CIRCGENETICS.114.000650. Epub 2014 Nov 18.
- Background: PubMed 36947466Marcus GM, Rosenthal DG, Nah G, Vittinghoff E, Fang C, Ogomori K, Joyce S, Yilmaz D, Yang V, Kessedjian T, Wilson E, Yang M, Chang K, Wall G, Olgin JE. Acute Effects of Coffee Consumption on Health among Ambulatory Adults. N Engl J Med. 2023 Mar 23;388(12):1092-1100. doi: 10.1056/NEJMoa2204737.
- Individual participant dataSharing planned: Undecided
Related trials for Heart Diseases
RecruitingObservational study
Atrial Fibrillation Patients Treated With Catheter Ablation
Atrial Fibrillation, Atrial Fibrillation Recurrent
RecruitingObservational study
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias
Arrhythmias, Cardiac
Not yet recruitingObservational study
Heart and Brain Blood Flow in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Recruiting
ELEVATE-HFpEF Clinical Study
Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss and Anxiety
Recurrent Pregnancy Loss(RPL), Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jeffrey E Olgin, MD principal investigator
University of California, San Francisco
Gregory Marcus, MD principal investigator
University of California, San Francisco
Vasanth Vedantham, MD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Diseases and Cardiac Diseases, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Establish and Maintain a Centralized Biorepository (time frame: Up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06976502, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.